etrolizumab (RG7413) - Roche
Etrolizumab: NME submission for ulcerative colitis in US in 2021 (Roche) - Apr 17, 2019 - Q1 2019 Results: Regulatory submission for ulcerative colitis in EU in 2021; Regulatory submissions for Crohn's disease in US and EU in 2022 or later 
BLA • European regulatory
https://www.roche.com/dam/jcr:f03df0f2-852c-47a5-9924-343bfb239c37/en/irp190417.pdf
 
Apr 17, 2019
 
 
64bebfbf-144c-4183-83b1-ea91a21baeb1.jpg